First Citizens Bank & Trust Co. Has $228,000 Stake in Sotera Health (NASDAQ:SHC)

First Citizens Bank & Trust Co. lifted its position in shares of Sotera Health (NASDAQ:SHC) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,689 shares of the company’s stock after buying an additional 2,402 shares during the period. First Citizens Bank & Trust Co.’s holdings in Sotera Health were worth $228,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. True Wealth Design LLC bought a new stake in Sotera Health during the 3rd quarter worth about $32,000. GAMMA Investing LLC raised its holdings in Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after acquiring an additional 1,660 shares in the last quarter. Point72 DIFC Ltd boosted its position in Sotera Health by 556.6% during the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after purchasing an additional 5,544 shares during the last quarter. Capital Performance Advisors LLP bought a new position in Sotera Health in the third quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Sotera Health during the 2nd quarter worth approximately $130,000. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Stock Performance

Shares of SHC stock opened at $13.75 on Wednesday. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 55.00 and a beta of 1.92. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The company has a 50-day simple moving average of $13.25 and a 200 day simple moving average of $14.53.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.18 EPS. On average, sell-side analysts predict that Sotera Health will post 0.61 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Sotera Health in a research report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective for the company. Finally, Citigroup raised their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Sotera Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.